[go: up one dir, main page]

ATE352319T1 - Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor - Google Patents

Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor

Info

Publication number
ATE352319T1
ATE352319T1 AT02787572T AT02787572T ATE352319T1 AT E352319 T1 ATE352319 T1 AT E352319T1 AT 02787572 T AT02787572 T AT 02787572T AT 02787572 T AT02787572 T AT 02787572T AT E352319 T1 ATE352319 T1 AT E352319T1
Authority
AT
Austria
Prior art keywords
inhibitor
combination
cyclooxygenase
histone deacetylase
relates
Prior art date
Application number
AT02787572T
Other languages
English (en)
Inventor
Ying-Nan Pan Chen
Peter Lassota
Alexander Wallace Wood
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE352319T1 publication Critical patent/ATE352319T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT02787572T 2001-11-06 2002-11-05 Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor ATE352319T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33301601P 2001-11-06 2001-11-06
US41931402P 2002-10-17 2002-10-17

Publications (1)

Publication Number Publication Date
ATE352319T1 true ATE352319T1 (de) 2007-02-15

Family

ID=26988512

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02787572T ATE352319T1 (de) 2001-11-06 2002-11-05 Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor

Country Status (22)

Country Link
US (3) US7402603B2 (de)
EP (1) EP1443967B1 (de)
JP (1) JP4413614B2 (de)
KR (1) KR100937064B1 (de)
CN (1) CN100457183C (de)
AT (1) ATE352319T1 (de)
AU (1) AU2002351844B2 (de)
BR (1) BR0213932A (de)
CA (1) CA2461373A1 (de)
CY (1) CY1106508T1 (de)
DE (1) DE60217895T2 (de)
DK (1) DK1443967T3 (de)
ES (1) ES2280597T3 (de)
HU (1) HUP0402370A3 (de)
IL (2) IL160970A0 (de)
MX (1) MXPA04004312A (de)
NO (1) NO20042148L (de)
NZ (1) NZ544689A (de)
PL (1) PL205853B1 (de)
PT (1) PT1443967E (de)
RU (1) RU2311200C2 (de)
WO (1) WO2003039599A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) * 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
AR043850A1 (es) * 2003-04-17 2005-08-17 Bayer Pharmaceuticals Corp Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos
JP2006528952A (ja) * 2003-05-21 2006-12-28 ノバルティス アクチエンゲゼルシャフト ヒストンデアセチラーゼ阻害剤と化学療法剤の組み合わせ
EP1491188A1 (de) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topische Verwendung von Valproinsäure zur Behandlung von Hauterkrankungen
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2006016637A1 (ja) * 2004-08-11 2006-02-16 Kyorin Pharmaceutical Co., Ltd. 新規環状アミノ安息香酸誘導体
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2008023438A1 (fr) * 2006-08-25 2008-02-28 Asahi Glass Co., Ltd. Procédé servant à produire du 1,2-dialcoxy-3-fluorobenzène
US7786330B2 (en) 2005-02-28 2010-08-31 Asahi Glass Company, Limited Process for producing 1,2-dialkoxy-3-fluorobenzene
EP1896436A2 (de) * 2005-05-11 2008-03-12 Takeda San Diego, Inc. Inhibitoren der histondeacetylase
EP1904452A2 (de) 2005-07-14 2008-04-02 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
EP1743654A1 (de) * 2005-07-15 2007-01-17 TopoTarget Germany AG Verwendung von Histon Deacetylase-Hemmer zusammen mit NSAIDen zur Behandlung von Krebs und/oder Entzündungskrankheiten
WO2007016136A2 (en) * 2005-07-28 2007-02-08 Nitromed, Inc. Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US7989639B2 (en) * 2006-06-12 2011-08-02 Novartis Ag Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
MX2008015900A (es) * 2006-06-12 2009-03-06 Novartis Ag Polimorfos de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amin o]metil]fenil]-2e-2-propenamida.
EP2394991B1 (de) 2006-06-12 2015-09-23 Novartis AG Verfahren zur Herstellung von Ausgangsmaterialien für N-Hydroxy-3-[4-[2-(2-methyl-1H-indol-3-yl)ethylaminomethyl]-phenyl]-2E-2-propenamid
CA2654936A1 (en) * 2006-06-28 2008-01-03 Novartis Ag Use of hdac inhibitors for the treatment of lymphomas
BRPI0806365B8 (pt) 2007-02-06 2021-05-25 Lixte Biotechnology Holdings Inc composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
WO2008100985A2 (en) * 2007-02-15 2008-08-21 Novartis Ag Combination of lbh589 with other therapeutic agents for treating cancer
EP2200439B1 (de) 2007-10-01 2017-03-22 Lixte Biotechnology, Inc. Hdac-hemmer
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
US8058268B2 (en) 2008-08-01 2011-11-15 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
RU2640416C2 (ru) * 2012-04-16 2018-01-09 Тоа Эйо Лтд. Бициклическое соединение
MX2015014249A (es) 2013-04-09 2016-06-02 Lixte Biotechnology Inc Formulaciones de oxabicicloheptanos y oxabicicloheptenos.
SG11201707418WA (en) 2015-03-13 2017-10-30 Forma Therapeutics Inc Alpha-cinnamide compounds and compositions as hdac8 inhibitors
CN110234647B (zh) 2016-12-08 2023-05-23 利克斯特生物技术公司 用于调节免疫应答的氧杂双环庚烷
CN115108926B (zh) * 2022-04-02 2023-06-20 上海工程技术大学 一种用于制备厄达替尼的中间体化合物及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)

Also Published As

Publication number Publication date
DK1443967T3 (da) 2007-04-16
EP1443967A1 (de) 2004-08-11
CA2461373A1 (en) 2003-05-15
ES2280597T3 (es) 2007-09-16
DE60217895T2 (de) 2007-07-05
HUP0402370A3 (en) 2008-04-28
US20080227845A1 (en) 2008-09-18
US20050032899A1 (en) 2005-02-10
KR100937064B1 (ko) 2010-01-15
NO20042148L (no) 2004-08-04
JP4413614B2 (ja) 2010-02-10
AU2002351844B2 (en) 2006-12-21
CN1578674A (zh) 2005-02-09
US7402603B2 (en) 2008-07-22
RU2311200C2 (ru) 2007-11-27
WO2003039599A1 (en) 2003-05-15
HUP0402370A2 (hu) 2005-02-28
CN100457183C (zh) 2009-02-04
BR0213932A (pt) 2004-08-31
MXPA04004312A (es) 2005-05-16
RU2004117170A (ru) 2005-04-20
JP2005510517A (ja) 2005-04-21
DE60217895D1 (en) 2007-03-15
EP1443967B1 (de) 2007-01-24
IL160970A0 (en) 2004-08-31
KR20050043744A (ko) 2005-05-11
PL205853B1 (pl) 2010-06-30
CY1106508T1 (el) 2012-01-25
IL160970A (en) 2010-06-30
PT1443967E (pt) 2007-04-30
NZ544689A (en) 2007-08-31
US20090192211A1 (en) 2009-07-30
PL368539A1 (en) 2005-04-04

Similar Documents

Publication Publication Date Title
ATE352319T1 (de) Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor
MXPA05012464A (es) Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
BR9914044A (pt) ésteres tetrahidropirido
ATE451369T1 (de) Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
DE50310516D1 (de) Fredericamycin-derivate
BR0309355A (pt) 2-(2,6-diclorofenil)-diarilimidazóis
WO2003106381A3 (en) ADAM 10 HUMAN INHIBITORS
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
JO2434B1 (en) New retinoids to treat emphysema
ATE438618T1 (de) Inhibitoren von humanem adam-10
BRPI0408466A (pt) composições farmacêuticas de inibidores de cetp e uso dos referidos inibidores
WO2007024574A3 (en) Topical formulations of histone deacetylase inhibitors and methods of using the same
BR9815596A (pt) Composto, composição farmacêutica, método de tratamento de doenças inflamatórias e método de tratamento de condição ou doença mediada por mmps e/ou tnf e/ou agrecanase
BR0307629A (pt) Métodos e composições para tratar condições hiperproliferativas
ES2124983T3 (es) Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
ATE345790T1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
ATE423102T1 (de) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer
ATE453614T1 (de) Sphingolipiden
PL367707A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
DE602004008247D1 (de) Zusammensetzung die tamsulosin und ein nichtsteroides entzündungshemmendes mittel enthält
PT1594456E (pt) Utilização de uma composição contendo óxido de vitamina k1 ou um seu derivado para tratamento e/ou prevenção de lesões dermatológicas em mamíferos
ECSP045071A (es) Combinacion de inhibidor de ciclooxigenasa-2/inhibidor de desacetilasa de histona

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1443967

Country of ref document: EP